Fresenius benefits from drug shortages; Perrigo unloads laxative plant;

> The German healthcare company Fresenius says it realized a 20% jump in first-half earnings in part because its injectable generic drugs unit Kabi has jumped on shortages presented by production problems at competitors. Story

> Contract manufacturer AMRI ($AMRI) says its U.S. work grew $2.2 million in the second quarter, although across all segments it saw a 2% decline in revenue to $42.4 million. Story

> Dukal has instituted a nationwide, voluntary recall of certain lots of its benzalkonium chloride swabs and antiseptic wipes manufactured by Jianerkang Medical Dressing because they may be contaminated with Burkholderia cepacia bacteria. Release

> The European Medicines Agency (EMA) says it is cooperating more with pharmaceutical regulators in Japan on plant inspections as well as many other projects. Story

And Finally... OTC drugmaker Perrigo has sold a manufacturing plant in Florida where it makes laxatives and douche products to Medline Industries, maker of Curad bandages. Story

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.